Peel Hunt Reiterates Add Rating for hVIVO (LON:HVO)

hVIVO (LON:HVO)‘s stock had its “add” rating reissued by investment analysts at Peel Hunt in a research report issued to clients and investors on Tuesday, MarketBeat reports. They presently have a GBX 10 target price on the stock. Peel Hunt’s price objective indicates a potential upside of 56.25% from the stock’s previous close.

Separately, Shore Capital reduced their price objective on hVIVO from GBX 35 to GBX 25 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, hVIVO currently has an average rating of “Buy” and an average price target of GBX 17.50.

hVIVO Stock Performance

hVIVO stock opened at GBX 6.40 on Tuesday. The firm has a 50 day simple moving average of GBX 7.74 and a 200-day simple moving average of GBX 10.66. The stock has a market cap of £43.98 million, a price-to-earnings ratio of 8.31 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. hVIVO has a 1-year low of GBX 6.20 and a 1-year high of GBX 29.80.

hVIVO (LON:HVO) last posted its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. On average, analysts expect that hVIVO will post 1.5492958 EPS for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.